Genetic Technologies Limited · ASX:GTG
Genetic Technologies — H.C. Wainwright 22nd Annual Global Investment Conference 2020
17 slides from Genetic Technologies's conference presentation, Sep 16, 2020
Slide 1: H.C. Wainwright 22nd Annual Global Investment Conference
Technolog NASDAQ: GENE HC Wainwright & Co 22°4 Annual Global investment Contarenae 14-16 September 2020
Slide 2: Forward looking statements
Forward looking statements Technologies This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements
Slide 3: Genetic Technologies is a leader in genomics
cS oS lee See Genetic Technologies is a leader in genomics Over a decade of R&D surrounding the development of polygenic risk scores Company Snapshot: with an extensive Patent Portfolio Creator of Laboratory Developed Tests (LDT) supported by proprietary polygenic risk scores (PRS) platform CLIA cer
Slide 4: Polygenic (Genetic) Risk Score
Genetic Polygenic (Genetic) Risk Score Teoepieoes Our Platform Most common complex diseases (CCD) are a result of many genes acting in concert Polygenic Risk Score is a DNA based risk assessment (screening) tool that weighs a person’s odds of developing a CCD by inspecting the genome (DNA) Genomic a
Slide 5: Polygenic Risk Scores (PRS) Platform
Polygenic Risk Scores (PRS) Platform Genetic Technologies Proprietary platform developed over the past decade and supports multiple PRS tests targeting healthy individuals to identify serious disease risk. + PRSisa DNAbasedrisk assessmenttool that weighs a person's odds of developing common complex
Slide 6: Product test pipeline and status
Product test pipeline and status ace * Our platform supports risk predictive testing in major oncological, metabolic, regenerative and infectious disease indications (including COVID-19) * Our tests in market and development cover up to 70% off causes of morbidity and mortality in the US + GeneType
Slide 7: Disease coverage
Disease coverage J Genetic Technologies * Our product development strategy aims to provide coverage of the most significant causes of morbidity and mortality in the US * It covers up to 70% of causes of mortality Incidence of underlying causes of mortality in the US ‘SOURCE: NCHS, National Vital Sta
Slide 8: World-first polygenic risk test for breast cancer
GTG has developed a world-first polygenic risk » S235 .cies test for breast cancer Easy-to-use test solves Risk stratification enables precision screening and personalised prevention the compliance problem Simple cheek swab that help determine a woman’s risk of developing breast cancer ) genelype Id
Slide 9: World-first polygenic risk test for colorectal cancer
GTG has developed a world-first polygenic risk » S235 .cies test for colorectal cancer Easy-to-use test solves the compliance problem Risk stratification enables precision screening and personalised prevention genelype Clinically actionable results 5-year, 10-year and lifetime risk colorectal cancer
Slide 10: COVID-19 sdr (serious disease risk)
Genetic Technologies COVID-19 sdr (serious disease risk) _
Slide 11: COVID-19 at a glance
COVID-19 at a glance ¢ About 30 million confirmed COVID-19 cases worldwide, with a mortality of almost 1 million* * Pandemic management strategies vary depending on country, but mostly one size fits all approaches * New Normal = maintaining social restrictions (distancing/isolation) until a vaccine
Slide 12: COVID-19 sdr (Serious disease risk)
COVID-19 sdr (Serious disease risk) fainologies * COVID-19 sdr is Genetic Technology's COVID-19 Response — a low-cost, accurate assessment tool that is designed to assist in pandemic management in lieu of a vaccine * Itis the world’s first genomic test to predict the risk of hospitalization and of d
Slide 13: Development Progress To-Date
Development Progress To-Date Technologies COVID-19 sdr is cece The Test is in Beta designed to enable : ‘© + The first clinical kit due in Q3 2020 the targeting of limited vaccine resources to those 0) Fast-tracking development at highest risk of ERA + In discussions with major international reagent
Slide 14: GeneType use cases for COVID-19
g geneType Simple to implement Suitable for people aged 30-65 Designed to identify high risk and low risk individuals ra Can be offered as a priority to first responders, health workers, ‘ transport and food supply groups : Could prioritize early intervention of high risk groups who are infected wit
Slide 15: Intellectual property is a core advantage
Intellectual property is a core advantage J Genetic Technologies GTG has a strong patent portfolio covering the breast cancer risk assessment test 5 Patents granted in the US Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included in the BREVAGenplus® risk
Slide 16: The Next months
The Next 12 months: + Complete development of High density multi disease tests covering >70% mortality in western society using a single swab and delivering low cost, accurate risk data. + Establish new divisions: Oncology, Metabolic diseases, Cardiovascular disease, Mental health (including cogniti
Slide 17: Our board
Ou r board 8 Technologies @ Dr. Jerzy “George” Muchnicki Dr. Lindsay Wakefield MBBS MBBS Executive Director & Chief Executive Officer (Interim) Non — Executive Director F F Mr Nick Burrows Mr. Peter Rubinstein B.Com, FAICD, FCA, FGIA, FTIA, F Fin isinaieeie neni Non — Executive Director Chairman - N
Genetic Technologies — H.C. Wainwright 22nd Annual Global Investment Conference 2020 on 6ix